A shipment of the CoronaVac vaccine will be unloaded on December 18 from a cargo plane that has arrived from China at Guarulhos International Airport in Guarulhos, Brazil. Nelson Almeida / AFP / Getty Images
CoronaVac, the Covid-19 vaccine developed by the Chinese company Sinovac, has shown 78% effectiveness in phase 3 trials in Brazil, its local partner, the Butantan Institute, announced on Thursday.
“Today is a very important day for Brazil, for Brazilians, for life and health,” said Sao Paulo Governor Joao Doria during a press conference with state health officials and executives from the Butantane Institute.
“This result means that the vaccine developed by the Butantan Institute has a high level of efficiency and effectiveness in protecting the lives of Brazilians from Covid-19,” Doria also said.
13,000 healthcare workers in eight Brazilian states participated in the phase 3 trials. Butantane director Dimas Covas said the full CoronaVac data would be published in an unspecified scientific publication but did not provide a schedule, according to Reuters.
Doria also said his government, along with the Butantane Institute, has begun the process of applying for an emergency permit with ANVISA, Brazil’s national medicines agency, “with the aim of starting vaccination in São Paulo on Jan. 25”.
Although the effectiveness shortens the success rates of the vaccine candidates Pfizer / BioNTech and Moderna Covid-19, CoronaVac is easier to carry and can be stored at normal refrigerator temperatures, reports Reuters.